X4 Pharmaceuticals (XFOR) Stock Forecast, Price Target & Predictions
XFOR Stock Forecast
X4 Pharmaceuticals stock forecast is as follows: an average price target of $3.67 (represents a 416.90% upside from XFOR’s last price of $0.71) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
XFOR Price Target
The average price target for X4 Pharmaceuticals (XFOR) is $3.67 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $3.00. This represents a potential 416.90% upside from XFOR's last price of $0.71.
XFOR Analyst Ratings
According to 3 Wall Street analysts, X4 Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for XFOR stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
X4 Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 22, 2022 | - | Cantor Fitzgerald | $3.00 | $0.85 | 252.98% | 322.54% |
| Dec 11, 2022 | Edward Tenthoff | Piper Sandler | $3.00 | $0.93 | 222.58% | 322.54% |
| Nov 30, 2022 | - | H.C. Wainwright | $5.00 | $1.85 | 170.27% | 604.23% |
The latest X4 Pharmaceuticals stock forecast, released on Dec 22, 2022 by Cantor Fitzgerald company, set a price target of $3.00, which represents a 252.98% increase from the stock price at the time of the forecast ($0.85), and a 322.54% increase from XFOR last price ($0.71).
X4 Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.71 | $0.71 | $0.71 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of X4 Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to X4 Pharmaceuticals's last price of $0.71. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Dec 22, 2022 | Cantor Fitzgerald | - | Overweight | Initialise |
| Dec 11, 2022 | Piper Sandler | - | Overweight | Initialise |
X4 Pharmaceuticals's last stock rating was published by H.C. Wainwright on Jun 28, 2024. The company gave XFOR a "Buy" rating, the same as its previous rate.
X4 Pharmaceuticals Financial Forecast
X4 Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Mar 22 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $3.00M |
| Avg Forecast | $9.13M | $7.21M | $6.11M | $5.22M | $3.93M | $1.69M | $15.27M | - | $128.57K | $2.84M | $4.29M |
| High Forecast | $18.28M | $14.71M | $12.48M | $10.65M | $8.03M | $3.32M | $31.16M | - | $377.46K | $3.41M | $5.14M |
| Low Forecast | $4.08M | $3.41M | $2.89M | $2.47M | $1.86M | $710.57K | $7.23M | - | $1.08K | $2.27M | $3.43M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 7 | 5 | 13 | 20 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.70% |
X4 Pharmaceuticals's average Quarter revenue forecast for Jun 20 based on 13 analysts is $2.84M, with a low forecast of $2.27M, and a high forecast of $3.41M. XFOR's average Quarter revenue forecast represents a -5.26% decrease compared to the company's last Quarter revenue of $3.00M (Mar 20).
X4 Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Mar 22 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 7 | 5 | 13 | 20 |
| EBITDA | - | - | - | - | - | - | - | $-25.20M | $-21.58M | $-14.39M | $-10.37M |
| Avg Forecast | $5.48M | $4.32M | $3.67M | $3.13M | $2.36M | $1.01M | $9.16M | - | $-17.84M | $-13.78M | $-13.48M |
| High Forecast | $10.97M | $8.83M | $7.49M | $6.39M | $4.82M | $1.99M | $18.70M | - | $-14.27M | $-11.03M | $-10.78M |
| Low Forecast | $2.45M | $2.05M | $1.74M | $1.48M | $1.12M | $426.34K | $4.34M | - | $-21.41M | $-16.54M | $-16.18M |
| Surprise % | - | - | - | - | - | - | - | - | 1.21% | 1.04% | 0.77% |
undefined analysts predict XFOR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than X4 Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
X4 Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Mar 22 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 7 | 5 | 13 | 20 |
| Net Income | - | - | - | - | - | - | - | $-19.13M | $-21.96M | $-15.14M | $-11.14M |
| Avg Forecast | $-24.76M | $-27.44M | $-29.45M | $-30.79M | $-32.13M | $-34.42M | $-1.43M | $-28.96M | $-20.32M | $-14.30M | $-14.48M |
| High Forecast | $-6.95M | $-8.66M | $-9.29M | $-9.71M | $-10.13M | $-30.37M | $-452.36K | $-27.03M | $-16.25M | $-11.44M | $-11.58M |
| Low Forecast | $-57.05M | $-64.60M | $-69.32M | $-72.47M | $-75.63M | $-36.45M | $-3.38M | $-32.82M | $-24.38M | $-17.16M | $-17.38M |
| Surprise % | - | - | - | - | - | - | - | 0.66% | 1.08% | 1.06% | 0.77% |
X4 Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. XFOR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
X4 Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Mar 22 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 7 | 5 | 13 | 20 |
| SG&A | - | - | - | - | - | - | - | $9.93M | $7.66M | $5.32M | $4.67M |
| Avg Forecast | $20.04M | $15.83M | $13.42M | $11.46M | $8.64M | $3.70M | $33.52M | - | $282.36K | $6.24M | $9.41M |
| High Forecast | $40.14M | $32.32M | $27.41M | $23.39M | $17.64M | $7.28M | $68.44M | - | $828.95K | $7.49M | $11.29M |
| Low Forecast | $8.95M | $7.49M | $6.36M | $5.42M | $4.09M | $1.56M | $15.87M | - | $2.36K | $4.99M | $7.53M |
| Surprise % | - | - | - | - | - | - | - | - | 27.14% | 0.85% | 0.50% |
X4 Pharmaceuticals's average Quarter SG&A projection for Jun 24 is $33.52M, based on 3 Wall Street analysts, with a range of $15.87M to $68.44M. The forecast indicates a 237.71% rise compared to XFOR last annual SG&A of $9.93M (Dec 23).
X4 Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Mar 22 | Jun 20 | Mar 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 6 | 3 | 7 | 5 | 13 | 20 |
| EPS | - | - | - | - | - | - | - | $-0.10 | $-0.65 | $-0.76 | $-0.56 |
| Avg Forecast | $-0.12 | $-0.14 | $-0.15 | $-0.15 | $-0.16 | $-0.17 | $-0.01 | $-0.15 | $-0.60 | $-0.72 | $-0.79 |
| High Forecast | $-0.03 | $-0.04 | $-0.05 | $-0.05 | $-0.05 | $-0.15 | $-0.00 | $-0.14 | $0.17 | $0.21 | $0.23 |
| Low Forecast | $-0.28 | $-0.32 | $-0.35 | $-0.36 | $-0.38 | $-0.18 | $-0.02 | $-0.17 | $-2.11 | $-2.52 | $-2.79 |
| Surprise % | - | - | - | - | - | - | - | 0.66% | 1.08% | 1.06% | 0.71% |
According to undefined Wall Street analysts, X4 Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to XFOR previous annual EPS of $NaN (undefined).
X4 Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| EFTR | eFFECTOR Therapeutics | $0.05 | $5.50 | 10900.00% | Buy |
| HEPA | Hepion Pharmaceuticals | $0.74 | $70.00 | 9359.46% | Buy |
| ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| PDSB | PDS Bio | $3.00 | $9.00 | 200.00% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| HOOK | HOOKIPA Pharma | $4.99 | $3.00 | -39.88% | Buy |
XFOR Forecast FAQ
Is X4 Pharmaceuticals a good buy?
Yes, according to 3 Wall Street analysts, X4 Pharmaceuticals (XFOR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of XFOR's total ratings.
What is XFOR's price target?
X4 Pharmaceuticals (XFOR) average price target is $3.67 with a range of $3 to $5, implying a 416.90% from its last price of $0.71. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will X4 Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for XFOR stock, the company can go up by 416.90% (from the last price of $0.71 to the average price target of $3.67), up by 604.23% based on the highest stock price target, and up by 322.54% based on the lowest stock price target.
Can X4 Pharmaceuticals stock reach $1?
XFOR's average twelve months analyst stock price target of $3.67 supports the claim that X4 Pharmaceuticals can reach $1 in the near future.
What are X4 Pharmaceuticals's analysts' financial forecasts?
X4 Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $20.89M (high $42.51M, low $9.8M), average EBITDA is $12.53M (high $25.51M, low $5.88M), average net income is $-67.986M (high $-40.958M, low $-115M), average SG&A $45.87M (high $93.36M, low $21.52M), and average EPS is $-0.339 (high $-0.204, low $-0.575). XFOR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $27.66M (high $56.12M, low $12.85M), average EBITDA is $16.6M (high $33.67M, low $7.71M), average net income is $-112M (high $-34.605M, low $-263M), average SG&A $60.76M (high $123.26M, low $28.23M), and average EPS is $-0.56 (high $-0.172, low $-1.312).
Did the XFOR's actual financial results beat the analysts' financial forecasts?
In terms of the last quarterly report (Mar 2020), X4 Pharmaceuticals's revenue was $3M, missing the average analysts' forecast of $4.29M by -30.00%. The company's EBITDA was $-10.37M, missing the average prediction of $-13.481M by -23.08%. X4 Pharmaceuticals's net income was $-11.138M, missing the average estimation of $-14.479M by -23.08%. The company's SG&A was $4.67M, missing the average forecast of $9.41M by -50.38%. Lastly, the company's EPS was $-0.56, missing the average prediction of $-0.793 by -29.36%